Skin, Bone & Muscle Mastermind - New York Oct 24, 2026

Longevitydocs Vision 2026

David LuuMD

Skin Regeneration: Stem Cells, Secretomes and Exosomes

Learning objectives:
- Describe how stem cells, platelet rich plasma, secretomes and extracellular vesicles act on skin, including paracrine signaling and cellular senescence.
- Differentiate product categories by source, characterization and regulatory status, including the line between a topical cosmetic and an injected biologic.
- Define valid endpoints in regenerative dermatology: histology, validated grading scales, senescence biomarkers, blinded vehicle-controlled design.

Saranya WylesMD, PhD

Gerotherapeutics for Skin, Muscle and Bone: The Pipeline

Learning objectives:
- Which aging-targeted drug classes have human data and which are still preclinical: senolytics, mTOR modulators, myostatin/activin inhibitors, NAD+ biology.
- How trials are designed when aging is not an FDA-recognized indication.
- Realistic timelines to clinical availability.

James PeyerPhD

Cellular Therapies: How Cell Products Are Actually Made

Learning Objectives:
- How placental, MSC, iPSC-derived and Muse cells differ in biology and clinical maturity.
- GMP manufacturing from donor screening to potency assays and release criteria.
- The line between a Section 351 biologic and a Section 361 product, and when an IND is required.

Robert HaririMD, PhD

Topical Rapamycin and Rapalogs in Skin Longevity

Learning Objectives:
- Explain mTORC1 versus mTORC2 inhibition and why intermittent dosing matters.
- Summerize human data for topical and low-dose systemic sirolimus in skin aging, and the limits of that data.
- Apply a monitoring approach: lipids, glucose, CBC, infection risk, CYP3A4 interactions.
- Identify patients who should not receive it, including perioperative patients given impaired wound healing.

Doris DayMD

The Aging Face, Biomarkers and Protocol

Learning Objectives:
- Assess the aging face as three structural layers: bone, fat, dermis.
- Sequence topicals, devices, injectables and systemic support, and place regenerative products according to current evidence.
- Match the intervention to the patient's dominant driver of aging.
- Recognize perception drift in the patient and in the physician.

Amanda HillMD

The GLP-1 Tax: Muscle and Bone on Incretin Therapy

Learning Objectives:
1 - Reinterpret the lean mass data:
- Critically appraise the lean mass fraction of weight lost in the major incretin trials (roughly 25–40%).
- Distinguish DXA "lean mass" (water, glycogen, organ mass, and muscle) from contractile skeletal muscle.
- Compare these losses with diet-only and bariatric weight loss.
2 - Identify the other players:
- Recognize the co-drivers of muscle loss that get blamed on the drug: inadequate protein as appetite collapses, inactivity, rapid titration, pre-existing sarcopenic obesity, and declining sex hormones, IGF-1, and mitochondrial function with age.
3 - Detect muscle decline earlier:
- Build a monitoring protocol that looks past the usual endpoints.
- Use underused bioimpedance markers, phase angle and the ECW/TBW ratio, as early signals of declining muscle quality.
- Recognize the limits of grip strength, which can be skewed by hand size, grip span, and arthritis. Know when chair-stand, gait speed, and DXA add value.
4 - Protect muscle and bone during therapy:
- Prescribe protein targets, resistance training, and titration pacing.
- Appraise the evidence and current regulatory status of hormonal and peptide adjuncts for preserving lean mass and bone.

Elizabeth YurthMD

Bone Loss: Screening, Markers and Sequencing

Learning Objectives:
- Identify patients who need earlier screening than age-based guidelines call for: perimenopausal women, men with low testosterone, premature ovarian insufficiency and Klinefelter syndrome, thyroid or parathyroid disorders, hypercalciuria and kidney disease, autoimmune, inflammatory and gut conditions as well as genetic risk
- Explain how hormones and inflammaging affect bone and muscle, including estrogen, testosterone, DHEA and cortisol.
- Tell the difference between diagnostic medical-grade DXA and body composition DXA done at fitness or longevity clinics, and know the limitations of each.
- Prescribe resistance and impact training, protein, vitamin D, calcium and magnesium, and clear up common myths about GLP-1 medications and bone loss.
- Recognize when to refer to endocrinology or a bone specialist.

Catherine JohnsonMD

Hormonal Transition and Collagen Loss

Learning Objectives:
- Describe the shared hormonal drivers of skin, bone and muscle decline at the menopausal transition.
- Summerize the collagen loss trajectory in the early postmenopausal years and the factors that accelerate it.
- Select topical and systemic interventions appropriate to a dermatology practice.
- Identify when to co-manage or refer for systemic hormone therapy.

Neely KhanMD, MS, FAAD

Latest devices protocol

Learning Objectives:
- Match laser, radiofrequency and ultrasound modalities to tissue target and indication.
- Identify the parameters that determine outcome: fluence, pulse duration, density, depth, passes.
- Combine and sequence modalities safely, and state where safety data are missing.
- Set treatment intervals based on tissue remodeling timelines.

Dan BelkinMD

Procedure Parameters and Pigment Risk Across Skin Types

Learning Objectives:
- Adjust device, injectable, and topical protocol parameters based on a patient's individual pigment risk profile, not phototype alone.
- Rank common aesthetic procedures, including peels, microneedling, and energy-based devices, by their actual pigment risk pathway.
- Apply pretreatment priming, parameter adjustments, and post-treatment regimens that reduce post-inflammatory hyperpigmentation.
- Identify patient specific pigment risk factors to inform counseling and consent conversations.

Naana BoakyeMD, CLD, MPH, FAAD

Biostimulators, Polynucleotides and Growth Factors

Learning Objectives:
- Assign an evidence tier to each biostimulator class by trial quality and endpoint.
- Compare polynucleotides with established biostimulators and growth factors, and state their US regulatory status.
- Select interval, injection plane and combinations for each class.
- Build a regenerative menu that holds up to peer review.

Kay DurairajMD, FACS